Venture capital warms to European biotechs

By Caroline Copley ZURICH (Reuters) – While a wave of stock market enthusiasm in the United States for biotech company flotations has yet to cross the Atlantic, venture capital appetite for promising European companies is returning. Biotech is hot on Wall Street, with the Nasdaq sector index up 43 percent this year, listed U.S. stocks scaling all-time highs and roughly 23 biotech companies going public. It’s a trend that is helping pique interest in exciting new science further afield. …